Early (or late?) to the starting gate
Despite a whipsaw market, three bravehearts are attempting to sell IPOs. The list includes diagnostic developer Biosite Diagnostics; Coulter Pharmaceutical, a developer of lymphoma therapies; and Epix Medical Inc. (formerly Metasyn), a developer of imaging agents. If sold as proposed, the companies would carve $74 million out of the funding pie. The companies may be hoping that fund managers will be looking for new opportunities when the whistle blows in January.
MARKET HOPEFULS: Biosite Diagnostics Inc. (Proposed:BSTE) filed to sell 2 million shares at $11-$13. A $12 price would value the company at $143 million. The